Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older

医学 去甲柔比星 柔红霉素 内科学 髓系白血病 单变量分析 多元分析 不利影响 白血病 外科 阿糖胞苷
作者
Claude Gardin,Sylvie Chevret,Cécile Pautas,Pascal Turlure,Emmanuel Raffoux,Xavier Thomas,Bruno Quesnel,Thierry de Revel,Stéphane de Botton,Nathalie Gachard,Aline Renneville,Nicolas Boissel,Claude Preudhomme,Christine Terré,Pierre Fenaux,Dominique Bordessoule,Karine Celli‐Lebras,Sylvie Castaigné,Hervé Dombret
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:31 (3): 321-327 被引量:74
标识
DOI:10.1200/jco.2011.40.3642
摘要

Although standard chemotherapy remains associated with a poor outcome in older patients with acute myeloid leukemia (AML), it is unclear which patients can survive long enough to be considered as cured. This study aimed to identify factors influencing the long-term outcome in these patients.The study included 727 older patients with AML (median age, 67 years) treated in two idarubicin (IDA) versus daunorubicin (DNR) Acute Leukemia French Association trials. Prognostic analysis was based on standard univariate and multivariate models and also included a cure fraction model to focus on long-term outcome.Age, WBC count, secondary AML, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and adverse-risk and favorable-risk AML subsets (European LeukemiaNet classification) all influenced complete remission (CR) rate and overall survival (OS). IDA random assignment was associated with higher CR rate, but not with longer OS (P = .13). The overall cure rate was 13.3%. Older age and ECOG-PS more than 1 negatively influenced cure rate, which was higher in patients with favorable-risk AML (39.1% v 8.0% in adverse-risk AML; P < .001) and those treated with IDA (16.6% v 9.8% with DNR; P = .018). The long-term impact of IDA was still observed in patients younger than age 65 years, although all of the younger patients in the DNR control arm received high DNR doses (cure rate, 27.4% for IDA v 15.9% for DNR; P = .049). In multivariate analysis, IDA random assignment remained associated with a higher cure rate (P = .04), together with younger age and favorable-risk AML, despite not influencing OS (P = .11).In older patients with AML, younger age, favorable-risk AML, and IDA treatment predict a better long-term outcome.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fan发布了新的文献求助10
刚刚
Ava的应助被zoeydonut采纳,获得10
刚刚
1秒前
2秒前
SciGPT的应助被τ涛采纳,获得10
2秒前
ddtmjj66完成签到 ,获得积分10
3秒前
3秒前
4秒前
丘比特的应助被于念采纳,获得10
4秒前
朱琳完成签到,获得积分10
4秒前
yun发布了新的文献求助30
5秒前
Terryzhou012完成签到,获得积分10
5秒前
6秒前
AireenBeryl531举报Charlee的求助涉嫌违规
6秒前
周锦程发布了新的文献求助10
6秒前
7秒前
9秒前
9秒前
白昭发布了新的文献求助10
10秒前
轩轾完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
13秒前
Lucas的应助被imneko采纳,获得10
14秒前
15秒前
帅气雅发布了新的文献求助10
15秒前
15秒前
16秒前
敏静发布了新的文献求助10
16秒前
白昭完成签到,获得积分10
16秒前
鱼总发布了新的文献求助10
16秒前
AireenBeryl531举报子yan的求助涉嫌违规
16秒前
朱琳发布了新的文献求助10
17秒前
18秒前
18秒前
18秒前
LSQ47发布了新的文献求助10
20秒前
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192841
求助须知:如何正确求助?哪些是违规求助? 9579236
关于积分的说明 21864289
捐赠科研通 7792410
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483927